{
    "clinical_study": {
        "@rank": "16504", 
        "arm_group": {
            "arm_group_label": "Before, After", 
            "arm_group_type": "Experimental", 
            "description": "The intervention is educational"
        }, 
        "brief_summary": {
            "textblock": "Intravenous Azythromycin therapy is considerably more expensive than oral therapy. The\n      investigators believe that intravenous therapy is prolonged more that necessary and that\n      oral therapy can be used much earlier in the course of the disease. The investigators plan\n      to check if that statement is true and intervene  in order to shorten the intravenous\n      therapy."
        }, 
        "brief_title": "Reducing Cost of Azythromycin by Transferring From IV to Oral Therapy", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Pneumonia", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "detailed_description": {
            "textblock": "The study will be performed in two stages. First a retrospective review of medical files of\n      50 patients hospitalized in the Haemek Medical Center with severe community acquired\n      pneumonia, treated with azythromycin. The files will be reviewed  for the criteria clinical\n      improvement, and for  azythromycin therapy, oral or intravenous.\n\n      The results of this review will help us define the appropriate behavioral intervention in\n      order to cause doctors to transfer from IV to PO therapy at the earliest appropriate time.\n      An intervention such as posters, pharmacy overseeing etc will be introduced. 3 months after\n      the intervention, an additional 50 files of pneumonia patients treated with azythromycin\n      will be reviewed in order to check the efficacy of the intervention.\n\n      The Review board and the NIH will be updated about the intervention, as soon as the\n      investigators have decided what intervention is appropriate"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients hospitalized with community acquired pneumonia treated by azythromycin\n\n        Exclusion Criteria:\n\n          -  Age under 18"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741909", 
            "org_study_id": "EMC-85-12-CTIL"
        }, 
        "intervention": {
            "arm_group_label": "Before, After", 
            "description": "after a baseline period, shorter  intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment", 
            "intervention_name": "education", 
            "intervention_type": "Behavioral"
        }, 
        "intervention_browse": {
            "mesh_term": "Azithromycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "azythromycin", 
            "community acquired pneumonia", 
            "intravenous", 
            "oral"
        ], 
        "lastchanged_date": "December 5, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Afula", 
                    "country": "Israel"
                }, 
                "name": "Haemek Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "Can the Cost of Azythromycin in be Reduced in Hospitalized Patients With Community Acquired Pneumonia by Quick Transfer From Intravenous to Oral Therapy?", 
        "overall_contact": {
            "email": "goldstein_le@clalit.org.il", 
            "last_name": "Lee H Goldstein, MD", 
            "phone": "97246494143"
        }, 
        "overall_official": {
            "affiliation": "Haemek Medical Center", 
            "last_name": "Lee H Goldstein, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Israeli Health Ministry Pharmaceutical Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "length of intravenous azythromycin treatment", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741909"
        }, 
        "responsible_party": {
            "investigator_affiliation": "HaEmek Medical Center, Israel", 
            "investigator_full_name": "Lee Goldstein", 
            "investigator_title": "Lee Goldstein MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "HaEmek Medical Center, Israel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "HaEmek Medical Center, Israel", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}